Allezoe Medical Holdings, Inc.
OTC Bulletin Board : ALZM

Allezoe Medical Holdings, Inc.

September 28, 2011 15:00 ET

Allezoe Medical Holdings (ALZM) Launches New Subsidiary in Latest Steps to Advance HPV Diagnostic Technology

BOCA RATON, FLORIDA--(Marketwire - Sept. 28, 2011) - Allezoe Medical Holdings, Inc. (OTCBB:ALZM) today announces the launching of its new wholly-owned subsidiary, SureScreen Medical, Inc.

SureScreen Medical will be responsible for taking Allezoe's HPV diagnostic technology through the appropriate trials and federal clearances. The subsidiary will then coordinate the strategy for a powerful market launch.

Allezoe is moving quickly following its announcement that it is acquiring SureScreen™ and other "see and treat" technology for on-the-spot diagnosis of Human Papillomavirus (HPV). HPV is linked to a number of cancers in both men and women; given the size and scope of the technology's applications, a subsidiary is appropriate to orchestrate the process.

Allezoe CEO Michael Gelmon says, "Many technologies do not see the light of day because companies fail to go through the proper processes and channels to commercialize what they have in hand. We are committed to a thorough process that can be rewarding for the healthcare field and our shareholders."

As the leading sexually transmitted infection, and a major cause of cervical cancer in women around the world, HPV is a growing public health concern. While SureScreen Medical will first focus on launching the diagnostic treatment for women in the global market, the company has already honed in on the applications of the technology for the men and veterinary fields.

Completing the regulatory process would open Allezoe's non-invasive technology to the $18B diagnosis and treatment market (10%) around the world. Allezoe hopes to see the market expand to its full size as patients and their providers gravitate toward the efficient, affordable technology.

Gelmon says, "With SureScreen Medical, we will leave no stone unturned. Naturally we're moving quickly – it's an exciting time and we want Allezoe to be the game-changer in how HPV is diagnosed around the world."

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. The Company assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules. The Company's SEC filings are available at

Contact Information